FR20C1029I2 - 4 phenyl-pyridines substituees pour le traitement de maladies associees a un recepteur nk-1 - Google Patents

4 phenyl-pyridines substituees pour le traitement de maladies associees a un recepteur nk-1

Info

Publication number
FR20C1029I2
FR20C1029I2 FR20C1029C FR20C1029C FR20C1029I2 FR 20C1029 I2 FR20C1029 I2 FR 20C1029I2 FR 20C1029 C FR20C1029 C FR 20C1029C FR 20C1029 C FR20C1029 C FR 20C1029C FR 20C1029 I2 FR20C1029 I2 FR 20C1029I2
Authority
FR
France
Prior art keywords
pyridines
receptor
treatment
substituted phenyl
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1029C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48094815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Publication of FR20C1029I1 publication Critical patent/FR20C1029I1/fr
Application granted granted Critical
Publication of FR20C1029I2 publication Critical patent/FR20C1029I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/025—Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
FR20C1029C 2011-11-29 2020-07-03 4 phenyl-pyridines substituees pour le traitement de maladies associees a un recepteur nk-1 Active FR20C1029I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564537P 2011-11-29 2011-11-29
US13/478,361 US8426450B1 (en) 2011-11-29 2012-05-23 Substituted 4-phenyl pyridines having anti-emetic effect
PCT/US2012/066778 WO2013082102A1 (en) 2011-11-29 2012-11-28 Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases

Publications (2)

Publication Number Publication Date
FR20C1029I1 FR20C1029I1 (fr) 2020-10-02
FR20C1029I2 true FR20C1029I2 (fr) 2023-12-29

Family

ID=48094815

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1029C Active FR20C1029I2 (fr) 2011-11-29 2020-07-03 4 phenyl-pyridines substituees pour le traitement de maladies associees a un recepteur nk-1

Country Status (50)

Country Link
US (7) US8426450B1 (el)
EP (1) EP2785706B1 (el)
JP (3) JP5635708B2 (el)
KR (1) KR101979050B1 (el)
CN (5) CN112961104A (el)
AP (1) AP2014007729A0 (el)
AR (1) AR089019A1 (el)
AU (1) AU2012346133B2 (el)
BR (1) BR112014012878B1 (el)
CA (1) CA2850644C (el)
CL (1) CL2014001280A1 (el)
CO (1) CO6990728A2 (el)
CR (1) CR20140312A (el)
CY (2) CY1118416T1 (el)
DK (1) DK2785706T3 (el)
DO (1) DOP2014000115A (el)
EA (1) EA026553B1 (el)
EC (1) ECSP14003642A (el)
ES (1) ES2603958T3 (el)
FR (1) FR20C1029I2 (el)
GE (1) GEP201706695B (el)
GT (1) GT201400102A (el)
HK (1) HK1199030A1 (el)
HR (1) HRP20161708T1 (el)
HU (2) HUE032288T2 (el)
IL (1) IL232859B (el)
IN (1) IN2014CN04907A (el)
JO (1) JO3202B1 (el)
LT (2) LT2785706T (el)
MA (1) MA35836B1 (el)
MD (1) MD4539C1 (el)
ME (1) ME02561B (el)
MX (1) MX2014006423A (el)
MY (1) MY165514A (el)
NI (1) NI201400043A (el)
NL (1) NL301047I2 (el)
PE (1) PE20141421A1 (el)
PH (1) PH12014501199B1 (el)
PL (1) PL2785706T3 (el)
PT (1) PT2785706T (el)
RS (1) RS55448B1 (el)
SG (1) SG11201402044XA (el)
SI (1) SI2785706T1 (el)
SM (1) SMT201600467B (el)
TN (1) TN2014000165A1 (el)
TW (1) TWI638806B (el)
UA (1) UA115136C2 (el)
UY (1) UY34472A (el)
WO (1) WO2013082102A1 (el)
ZA (1) ZA201404787B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024616A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating miild cognitive impairment (mci) and related discorders
AU2011338428B2 (en) 2010-12-07 2015-05-21 Allison Transmission, Inc. Energy storage system for hybrid electric vehicle
MY185061A (en) 2011-06-22 2021-04-30 Shionogi & Co Trpv1 antagonists including dihydroxy substituent and uses thereof
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
US20150315149A1 (en) * 2014-05-05 2015-11-05 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
US10005803B2 (en) 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
LT3435980T (lt) * 2016-06-06 2020-02-25 Helsinn Healthcare Sa Fiziologiškai subalansuotos injekcinės fosnetupitanto kompozicijos
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
MA54847A (fr) 2016-12-09 2021-12-08 Vertex Pharma Forme crystalline d'un n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide pour traiter la mucoviscidose
CN108619525B (zh) * 2017-03-15 2020-12-29 和龙 奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
CN107698500A (zh) * 2017-10-17 2018-02-16 扬子江药业集团四川海蓉药业有限公司 一种奈妥匹坦的制备方法
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
HUE062180T2 (hu) * 2018-01-12 2023-09-28 Orion Corp Palonosetron szemcsepp a hányinger és a hányás kezelésére vagy megelõzésére
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
CA3173697A1 (en) 2020-04-03 2021-10-07 Mike TROWER An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
BR112022024208A2 (pt) * 2020-06-02 2022-12-20 Nerre Therapeutics Ltd Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051181B1 (en) 1997-12-31 2004-03-17 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
PT1103545E (pt) 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
KR100501608B1 (ko) 2000-07-14 2005-07-18 에프. 호프만-라 로슈 아게 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
KR100602299B1 (ko) 2000-12-14 2006-07-14 에프. 호프만-라 로슈 아게 자가 유화성 지질 매트릭스
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CN101146775B (zh) * 2005-03-23 2012-07-18 弗·哈夫曼-拉罗切有限公司 用于呕吐的用作nk-i拮抗剂的代谢物
US20090114877A1 (en) * 2005-09-13 2009-05-07 Eisai R&D Management Co., Ltd. Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA108077C2 (xx) * 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
ES2623503T3 (es) * 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
WO2011084846A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
PL2646035T3 (pl) * 2010-12-02 2016-08-31 Univ Kansas Proleki 6-cykloheksylo-1-hydroksy-4-metylopirydyn-2(1h)-onu i ich pochodne
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof

Also Published As

Publication number Publication date
BR112014012878A2 (pt) 2017-06-13
MD4539B1 (ro) 2017-12-31
CN106986822B (zh) 2020-04-21
CR20140312A (es) 2014-08-27
ES2603958T3 (es) 2017-03-02
CA2850644C (en) 2020-08-11
CY2020017I2 (el) 2020-11-25
ME02561B (me) 2017-02-20
NL301047I2 (nl) 2023-08-01
GEP201706695B (en) 2017-07-10
MA35836B1 (fr) 2014-12-01
BR112014012878A8 (pt) 2021-06-15
AU2012346133B2 (en) 2016-10-06
CY1118416T1 (el) 2017-06-28
UA115136C2 (uk) 2017-09-25
CL2014001280A1 (es) 2014-11-07
IN2014CN04907A (el) 2015-09-18
JP2015017121A (ja) 2015-01-29
HUE032288T2 (hu) 2017-09-28
KR101979050B1 (ko) 2019-05-15
US8426450B1 (en) 2013-04-23
TW201331181A (zh) 2013-08-01
CA2850644A1 (en) 2013-06-06
SI2785706T1 (sl) 2017-01-31
GT201400102A (es) 2015-12-07
JP2014507446A (ja) 2014-03-27
LTC2785706I2 (lt) 2023-07-10
SG11201402044XA (en) 2014-09-26
CN112961104A (zh) 2021-06-15
AP2014007729A0 (en) 2014-06-30
US12071421B2 (en) 2024-08-27
PH12014501199A1 (en) 2014-09-08
NI201400043A (es) 2015-09-21
UY34472A (es) 2013-06-28
FR20C1029I1 (fr) 2020-10-02
KR20140103991A (ko) 2014-08-27
AU2012346133A1 (en) 2014-04-17
NL301047I1 (el) 2020-06-24
EA026553B1 (ru) 2017-04-28
DOP2014000115A (es) 2014-07-15
US10717721B2 (en) 2020-07-21
LTPA2020510I1 (lt) 2020-07-10
JP6074083B2 (ja) 2017-02-01
SMT201600467B (it) 2017-03-08
PT2785706T (pt) 2016-12-16
MD4539C1 (ro) 2018-07-31
MY165514A (en) 2018-03-28
PH12014501199B1 (en) 2014-09-08
AR089019A1 (es) 2014-07-23
MX2014006423A (es) 2014-09-08
CN106518924A (zh) 2017-03-22
EP2785706B1 (en) 2016-09-14
CN106986822A (zh) 2017-07-28
HUS2000032I1 (hu) 2020-09-28
JP5635708B2 (ja) 2014-12-03
JP2016147868A (ja) 2016-08-18
EA201400624A1 (ru) 2015-01-30
HRP20161708T1 (hr) 2017-02-10
CN111662330B (zh) 2023-05-12
US9908907B2 (en) 2018-03-06
DK2785706T3 (en) 2016-12-12
PL2785706T3 (pl) 2017-03-31
US20180194788A1 (en) 2018-07-12
TWI638806B (zh) 2018-10-21
BR112014012878B1 (pt) 2022-05-31
TN2014000165A1 (en) 2015-09-30
WO2013082102A1 (en) 2013-06-06
IL232859A0 (en) 2014-07-31
NZ623746A (en) 2016-07-29
CN104053652A (zh) 2014-09-17
US20200399240A1 (en) 2020-12-24
CN112979543A (zh) 2021-06-18
IL232859B (en) 2018-01-31
ECSP14003642A (es) 2015-12-31
CN111662330A (zh) 2020-09-15
ZA201404787B (en) 2015-12-23
LT2785706T (lt) 2016-12-12
US10208073B2 (en) 2019-02-19
US11312698B2 (en) 2022-04-26
US20130231315A1 (en) 2013-09-05
CY2020017I1 (el) 2020-11-25
US20170050993A1 (en) 2017-02-23
CO6990728A2 (es) 2014-07-10
US8895586B2 (en) 2014-11-25
CN106518924B (zh) 2019-10-08
MD20140059A2 (en) 2014-11-30
US20220401463A1 (en) 2022-12-22
JP6023146B2 (ja) 2016-11-09
EP2785706A1 (en) 2014-10-08
PE20141421A1 (es) 2014-10-03
HK1199030A1 (zh) 2015-06-19
JO3202B1 (ar) 2018-03-08
RS55448B1 (sr) 2017-04-28
US20190177296A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
FR20C1029I2 (fr) 4 phenyl-pyridines substituees pour le traitement de maladies associees a un recepteur nk-1
HK1252279A1 (zh) 5- ht3受體拮抗劑
SG11201401202YA (en) Antagonists of il17c for the treatment of inflammatory disorders
HK1209032A1 (en) Oxytocin receptor agonists for the treatment of cns diseases cns
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
HK1198580A1 (en) Novel therapeutic use of p75 receptor antagonists p75
CO6821933A2 (es) Antagonistas no competitivos de receptores nicotínicos
TH148777B (th) ฟิวชั่นโปรตีนสำหรับบำบัดความผิดปกติเกี่ยวกับเมทาบอลิซึม